Shanghai Pharmaceuticals (SHA:601607, HKG:2607) received approval from China's drug administration for the supplemental drug application of tranexamic acid injection after it passed the regulator's consistency evaluation, according to a Shanghai bourse filing on Tuesday.
The drug, which is used to treat bleeding caused by hyperfibrinolysis, was evaluated for its consistency in quality and efficiency.
The pharmaceutical company's Hong Kong shares rose less than 2% during morning trade.